A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease. Tab-cel (tabelecleucel), our lead program in Phase 3 clinical development in the U.S., has received marketing authorization approval (MAA) under the proprietary name Ebvallo for commercial sale in the European Economic Area (EEA) by the European Commission (EC), for commercial sale and use in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA), and for commercial sale and use in Switzerland by Swissmedic. We are the most advanced allogeneic T-cell immunotherapy company and intend to rapidly deliver off-the-shelf treatments to patients with high unmet medical need.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 129M | - | - |
| Net Income | 23M | -85M | -276M | -228M |
| EPS | $2.86 | $-11.41 | $-65.19 | $-56.00 |
| Free Cash Flow | 0 | -69M | -194M | -275M |
| ROIC | 77.6% | -60.4% | -131.7% | -175.0% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | -2.12 | -2.67 | 1.97 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | 26M | -83M | -276M | -281M |
| Operating Margin | 0.0% | -64.7% | - | - |
| ROE | 0.0% | - | - | -180.3% |
| Shares Outstanding | 7M | 7M | 4M | 4M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | 129M | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -281M | -276M | -83M | 26M |
| Op. Margin | N/A | N/A | -64.7% | 0.0% |
| Net Income | -228M | -276M | -85M | 23M |
| Net Margin | N/A | N/A | -66.2% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -175.0% | -131.7% | -60.4% | 77.6% |
| ROE | -180.3% | N/A | N/A | 0.0% |
| ROA | -60.7% | -166.8% | -62.2% | 77.6% |
| Cash Flow | ||||
| Op. Cash Flow | -270M | -193M | -69M | -70M |
| Free Cash Flow | -275M | -194M | -69M | 0 |
| Owner Earnings | -330M | -243M | -101M | -102M |
| CapEx | 4.2M | 1.2M | 246K | 0 |
| Maint. CapEx | 5.7M | 4.8M | 5.1M | 5.1M |
| Growth CapEx | 0 | 0 | 0 | 0 |
| D&A | 5.7M | 4.8M | 5.1M | 5.1M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 54M | 45M | 27M | 27M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | N/A | N/A | N/A | -14M |
| Cash & Equiv. | N/A | N/A | N/A | 14M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 1.97 | -2.67 | -2.12 | 0.00 |
| Interest Coverage | -752.0 | -52.2 | -18.1 | -18.1 |
| Equity | 127M | -99M | -97M | -37M |
| Total Assets | 376M | 166M | 109M | 30M |
| Total Liabilities | 250M | 265M | 206M | 67M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -1.7B | -2.0B | -2.1B | -2.1B |
| Working Capital | 216M | -40M | -70M | -70M |
| Current Assets | 295M | 102M | 65M | 65M |
| Current Liabilities | 79M | 142M | 135M | 135M |
| Per Share Data | ||||
| EPS | -56.00 | -65.19 | -11.41 | 2.86 |
| Owner EPS | -80.93 | -57.41 | -13.46 | -14.11 |
| Book Value | 31.06 | -23.43 | -13.00 | -5.08 |
| Cash Flow/Share | -66.33 | -45.56 | -9.18 | 3.95 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 4.1M | 4.2M | 7.5M | 7.2M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | 1.8 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | 0.9 |
| Price/Book | 2.4 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 0.7 | N/A |
| FCF Yield | -90.1% | -334.0% | -75.8% | N/A |
| Market Cap | 305M | 58M | 91M | 37M |
| Avg. Price | 178.30 | 55.62 | 12.91 | 5.15 |
| Year-End Price | 74.75 | 13.73 | 12.15 | 5.15 |
Atara Biotherapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Atara Biotherapeutics, Inc. (ATRA) has a 5-year average return on invested capital (ROIC) of -122.4%. This is below average and may indicate limited pricing power.
Atara Biotherapeutics, Inc. (ATRA) has a market capitalization of $37M. It is classified as a small-cap stock.
Atara Biotherapeutics, Inc. (ATRA) does not currently pay a regular dividend.
Atara Biotherapeutics, Inc. (ATRA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Atara Biotherapeutics, Inc. (ATRA) reported annual revenue of $129 million in its most recent fiscal year, based on SEC EDGAR filings.
Atara Biotherapeutics, Inc. (ATRA) has a net profit margin of -66.2%. The company is currently unprofitable.
Atara Biotherapeutics, Inc. (ATRA) generated $-69 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Atara Biotherapeutics, Inc. (ATRA) reported earnings per share (EPS) of $-11.41 in its most recent fiscal year.
The Ledger Terminal provides 3 years of financial data for Atara Biotherapeutics, Inc. (ATRA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Atara Biotherapeutics, Inc. (ATRA) has a book value per share of $-13.00, based on its most recent annual SEC filing.